Xeris Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $74,380 | $71,539 | $60,119 | $60,099 |
Gross Profit | 63,384 | 56,930 | 51,391 | 50,621 |
EBITDA | 11,078 | 8,594 | 1,228 | 5,723 |
EBIT | 7,889 | 5,430 | -1,915 | 2,590 |
Net Income | 621 | -1,928 | -9,220 | -5,113 |
Net Change In Cash | 74,380 | 71,539 | 60,119 | 60,099 |
Free Cash Flow | 18,069 | 10,044 | -10,044 | 1,755 |
Cash | 91,598 | 59,285 | 58,440 | 71,621 |
Basic Shares | 177,617 | 155,972 | 152,445 | 149,092 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $203,070 | $163,914 | $110,248 | $49,590 |
Gross Profit | 166,238 | 135,269 | 87,614 | 36,272 |
EBITDA | -13,994 | -23,735 | -69,314 | -113,666 |
EBIT | -26,619 | -36,895 | -81,982 | -115,545 |
Net Income | -54,836 | -62,255 | -94,660 | -122,725 |
Net Change In Cash | 203,070 | 163,914 | 110,248 | 49,590 |
Free Cash Flow | -37,849 | -49,286 | -103,415 | -96,620 |
Cash | 71,621 | 67,449 | 121,966 | 67,271 |
Basic Shares | 146,773 | 137,674 | 135,628 | 79,027 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0.003 |
2025-06-30 | -$0.01 |
2025-03-31 | -$0.06 |
2024-12-31 | -$0.03 |
